BRKR (Bruker) stock outlook for 2026. A qualitative deep dive into Bruker's near-monopoly in high-field NMR, timsTOF mass spec growth, MALDI Biotyper recurring consumables, and NanoString spatial biology weighed against M&A leverage, margin dilution, and NIH funding risk.
Repligen (RGEN) 2026 stock outlook. A deep, practitioner-level look at the recurring razor-and-blade consumables model across filtration, chromatography ligands and single-use flow paths, the post-pandemic destocking normalization, antibody and GLP-1 volume recovery, the peer fight with Danaher Cytiva, Sartorius and Thermo Fisher, and the real risks.
Revvity (RVTY) 2026 stock analysis: the PerkinElmer rebrand, a razor-blade recurring-revenue model across Diagnostics and Life Sciences, the newborn-screening franchise moat, and the China VBP and biotech-funding risks that move the story.